About Us
Advalife Science Group
HOME
>
About Us
>
Advalife Science Group
From research and drug discovery through manufacturing and CMC to clinical trials, clinical development, patient care and real-world data, each organisation contributes its own specialist function.
Each organisation holds its own expertise and its own role, and together they form a development structure that connects research, drug discovery and clinical practice.
Contents
01
How research, development and clinical practice connect
03
How we collaborate
02
Roles
Contents
01
How research, development and clinical practice connect
02
Roles
03
How we collaborate
Structure
How research, development and clinical practice connect
DISCOVERY & RESEARCH
General Incorporated Association Advalife Science
Responsible for the discovery and development of new drug candidates, scientific validation, intellectual property, and joint research and academic collaboration.
MANUFACTURING & CMC
NOVARK BIO Co.,Ltd
Responsible for pharmaceutical functions including manufacturing and CMC, process development, formulation and injectable development, and quality control.
CLINICAL DEVELOPMENT & CRO
Medbis Co., Ltd.
Responsible for clinical trials and clinical development support, and for the sale and supply of research materials.
CLINICAL NETWORK & RWD
Sinclair Clinical Network
Through three healthcare institutions — Ginza, Shinsaibashi and Blue Front Shibaura — it provides the clinical base for patient care, everyday clinical practice and the real-world data that follows from it.
Roles
Drug discovery research and intellectual property
General Incorporated Association Advalife Science
Manufacturing and CMC
NOVARK BIO Co.,Ltd
Clinical development support / supply of research materials
Medbis Co., Ltd.
Patient care, clinical practice and real-world data
Sinclair Clinical Network (three institutions)
Collaboration
How we collaborate
Each company and each healthcare institution keeps its own legal responsibilities and its own expertise, and shares the information and the decisions that each stage of development requires. What is observed in clinical practice becomes a research hypothesis, and research results are carried through to intellectual property, joint research, licensing and clinical development, keeping research, drug discovery and clinical practice in continuous circulation.
Nor do we aim to keep everything within the group. We advance each development programme through collaboration with universities, research institutions and pharmaceutical companies in Japan and abroad.
ABOUT US
Contact us
Enquiries about the organisation, research collaboration and business partnerships, and media requests are all received here.